Skip to NavigationSkip to content

Pharmafile - Research and Development News

Roche has lifted the curtain on new data which shows that its investigational survival motor neuron-2 (SMN2) splicing modifier risdiplam met its...
The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR agonist tropifexor in the...
Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the treatment of gastric cancer, and they...
In our rundown of the week's most popular stories, President Donald Trump has named his first choice for the top job at the FDA, and Novartis'...
Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent that...
AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient...
Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line maintenance...
Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply up to 500,000 regimens of...
AstraZeneca has doubled down on its commitment to the Chinese region with the announcement of three “large-scale initiatives” in the country designed...
Endo International has announced its “CEO succession plan”, revealing that the company’s Chief Executive and President Paul V Campanelli has tendered...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches